Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization.

Boutin JA, Bouillaud F, Janda E, Gacsalyi I, Guillaumet G, Hirsch EC, Kane DA, Nepveu F, Reybier K, Dupuis P, Bertrand M, Chhour M, Le Diguarher T, Antoine M, Brebner K, Da Costa H, Ducrot P, Giganti A, Goswami V, Guedouari H, Michel PP, Patel A, Paysant J, Stojko J, Viaud-Massuard MC, Ferry G.

Mol Pharmacol. 2019 Mar;95(3):269-285. doi: 10.1124/mol.118.114231. Epub 2018 Dec 19.

2.

Persistent therapeutic effect of a novel α5-GABAA receptor antagonist in rodent preclinical models of vascular cognitive impairment.

Gacsályi I, Móricz K, Gigler G, Megyeri K, Machado P, Antoni FA.

Eur J Pharmacol. 2018 Sep 5;834:118-125. doi: 10.1016/j.ejphar.2018.07.015. Epub 2018 Jul 21.

PMID:
30012500
3.

Loop F of the GABAA receptor alpha subunit governs GABA potency.

Pálvölgyi A, Móricz K, Pataki Á, Mihalik B, Gigler G, Megyeri K, Udvari S, Gacsályi I, Antoni FA.

Neuropharmacology. 2018 Jan;128:408-415. doi: 10.1016/j.neuropharm.2017.10.042. Epub 2017 Nov 3.

PMID:
29109059
4.

Selective inhibition of extra-synaptic α5-GABAA receptors by S44819, a new therapeutic agent.

Etherington LA, Mihalik B, Pálvölgyi A, Ling I, Pallagi K, Kertész S, Varga P, Gunn BG, Brown AR, Livesey MR, Monteiro O, Belelli D, Barkóczy J, Spedding M, Gacsályi I, Antoni FA, Lambert JJ.

Neuropharmacology. 2017 Oct;125:353-364. doi: 10.1016/j.neuropharm.2017.08.012. Epub 2017 Aug 12.

PMID:
28807671
5.

Behavioural pharmacology of the α5-GABAA receptor antagonist S44819: Enhancement and remediation of cognitive performance in preclinical models.

Gacsályi I, Móricz K, Gigler G, Wellmann J, Nagy K, Ling I, Barkóczy J, Haller J, Lambert JJ, Szénási G, Spedding M, Antoni FA.

Neuropharmacology. 2017 Oct;125:30-38. doi: 10.1016/j.neuropharm.2017.07.005. Epub 2017 Jul 8.

PMID:
28694097
6.

Loop-F of the α-subunit determines the pharmacologic profile of novel competitive inhibitors of GABAA receptors.

Mihalik B, Pálvölgyi A, Bogár F, Megyeri K, Ling I, Barkóczy J, Bartha F, Martinek TA, Gacsályi I, Antoni FA.

Eur J Pharmacol. 2017 Mar 5;798:129-136. doi: 10.1016/j.ejphar.2017.01.033. Epub 2017 Jan 31.

PMID:
28153485
7.

A novel GABA(A) alpha 5 receptor inhibitor with therapeutic potential.

Ling I, Mihalik B, Etherington LA, Kapus G, Pálvölgyi A, Gigler G, Kertész S, Gaál A, Pallagi K, Kiricsi P, Szabó É, Szénási G, Papp L, Hársing LG, Lévay G, Spedding M, Lambert JJ, Belelli D, Barkóczy J, Volk B, Simig G, Gacsályi I, Antoni FA.

Eur J Pharmacol. 2015 Oct 5;764:497-507. doi: 10.1016/j.ejphar.2015.07.005. Epub 2015 Jul 11.

PMID:
26169564
8.

Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.

Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA.

Neuropharmacology. 2013 Jan;64:254-63. doi: 10.1016/j.neuropharm.2012.07.017. Epub 2012 Jul 21.

PMID:
22824189
9.

Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT₇ receptor antagonist activity.

Volk B, Gacsályi I, Pallagi K, Poszávácz L, Gyönös I, Szabó E, Bakó T, Spedding M, Simig G, Szénási G.

J Med Chem. 2011 Oct 13;54(19):6657-69. doi: 10.1021/jm200547z. Epub 2011 Sep 16.

PMID:
21859099
10.

Deramciclane improves object recognition in rats: potential role of NMDA receptors.

Kertész S, Kapus G, Gacsályi I, Lévay G.

Pharmacol Biochem Behav. 2010 Feb;94(4):570-4. doi: 10.1016/j.pbb.2009.11.012. Epub 2009 Dec 3.

PMID:
19963003
11.

5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism.

Doleviczényi Z, Vizi ES, Gacsályi I, Pallagi K, Volk B, Hársing LG Jr, Halmos G, Lendvai B, Zelles T.

Neurochem Res. 2008 Nov;33(11):2364-72. doi: 10.1007/s11064-008-9796-4. Epub 2008 Jul 29.

PMID:
18663573
12.

Chronic mild stress generates clear depressive but ambiguous anxiety-like behaviour in rats.

Kompagne H, Bárdos G, Szénási G, Gacsályi I, Hársing LG, Lévay G.

Behav Brain Res. 2008 Nov 21;193(2):311-4. doi: 10.1016/j.bbr.2008.06.008. Epub 2008 Jun 11.

PMID:
18590771
13.

Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues.

Kapus GL, Gacsályi I, Vegh M, Kompagne H, Hegedus E, Leveleki C, Hársing LG, Barkóczy J, Bilkei-Gorzó A, Lévay G.

Psychopharmacology (Berl). 2008 Jun;198(2):231-41. doi: 10.1007/s00213-008-1121-z. Epub 2008 Mar 25.

PMID:
18363046
14.

(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists.

Volk B, Barkóczy J, Hegedus E, Udvari S, Gacsályi I, Mezei T, Pallagi K, Kompagne H, Lévay G, Egyed A, Hársing LG Jr, Spedding M, Simig G.

J Med Chem. 2008 Apr 24;51(8):2522-32. doi: 10.1021/jm070279v. Epub 2008 Mar 25.

PMID:
18361484
15.

Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models.

Gigler G, Móricz K, Agoston M, Simó A, Albert M, Benedek A, Kapus G, Kertész S, Vegh M, Barkóczy J, Markó B, Szabó G, Matucz E, Gacsályi I, Lévay G, Hársing LG Jr, Szénási G.

Br J Pharmacol. 2007 Sep;152(1):151-60. Epub 2007 Jul 2.

16.

Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.

Megyeri K, Marko B, Sziray N, Gacsalyi I, Juranyi Z, Levay G, Harsing LG Jr.

Brain Res Bull. 2007 Mar 15;71(5):501-7. Epub 2006 Nov 27.

PMID:
17259019
17.

Glycine transporter type-1 and its inhibitors.

Harsing LG Jr, Juranyi Z, Gacsalyi I, Tapolcsanyi P, Czompa A, Matyus P.

Curr Med Chem. 2006;13(9):1017-44. Review.

PMID:
16611082
18.

Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy.

Jakus R, Graf M, Ando RD, Balogh B, Gacsalyi I, Levay G, Kantor S, Bagdy G.

Brain Res. 2004 May 22;1008(2):236-44.

PMID:
15145761
19.

Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist.

Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, Nicolas JP, Boutin J, Bózsing D, Egyed A, Tihanyi K, Spedding M, Szénási G.

Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34.

PMID:
15107597
20.

The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study.

Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G.

Pharmacol Biochem Behav. 2003 Mar;74(4):811-25.

PMID:
12667895
21.

Synthesis and evaluation of 5-HT(2A) and 5-HT(2C) receptor binding affinities of novel pyrimidine derivatives.

Bózsing D, Simonek I, Simig G, Jakóczi I, Gacsályi I, Lévay G, Tihanyi K, Schmidt E.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3097-9.

PMID:
12372510
22.

Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655.

Szabados T, Gigler G, Gacsályi I, Gyertyán I, Lévay G.

Brain Res Bull. 2001 Jun;55(3):387-91.

PMID:
11489346
23.

Duration of action of GYKI 52466 and its analogues in antiepileptic, anti-ischaemic and muscle relaxant tests.

Szabados T, Gigler G, Gyertyán I, Gacsályi I, Lévay G.

Neurobiology (Bp). 1999;7(1):87-8. No abstract available.

PMID:
10746257
24.

Behavioural studies with a highly emotional mouse strain newly bred in EGIS Pharmaceuticals Ltd.

Bilkei-Gorzó A, Müller G, Gyertyán I, Gacsályi I, Szabados T.

Neurobiology (Bp). 1998;6(4):461-2. No abstract available.

PMID:
10220784
25.

Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats.

Détári L, Szentgyörgyi V, Hajnik T, Szénási G, Gacsályi I, Kukorelli T.

Psychopharmacology (Berl). 1999 Mar;142(3):318-26.

PMID:
10208325
26.

Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function.

Varga G, Kordás K, Burghardt B, Gacsályi I, Szénási G.

Eur J Pharmacol. 1999 Feb 19;367(2-3):315-23.

PMID:
10079007
27.

Comparative clinical examination of Loderix (setastinum) and astemizole in pollenosis.

Herjavecz I, Karácsonyi E, Mülbacher S, Radics K, Szilágyi R, Gacsályi I.

Ther Hung. 1993;41(4):141-5.

PMID:
8029782
28.

[Neurologic tests in children having recovered from leukemia].

Schuler D, Bakos M, Kardos G, Koós R, Révész T, Somló P, Nagy C, Gacsályi I, Kálmánchey R.

Orv Hetil. 1989 Jul 30;130(31):1639-41. Hungarian.

PMID:
2771396
29.

Possible involvement of the dopaminergic system in the mode of action of the potential antidepressant trazium esilate.

Gyertyán I, Petöcz L, Bajnógel J, Szücs Z, Hegedüs M, Gyüre K, Gacsályi I, Krizsán D, Fekete MI.

Arzneimittelforschung. 1989 Jul;39(7):775-81.

PMID:
2551306
30.

EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects.

Gacsályi I, Petöcz L, Fekete MI, Bükkfálvi B, Görgenyi F, Arató M.

Pol J Pharmacol Pharm. 1988 Nov-Dec;40(6):613-9.

PMID:
2908364

Supplemental Content

Loading ...
Support Center